Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute
Articles
Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges
Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Safety Analysis
Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Efficacy Analysis
Alan Skarbnik, MD, and Ryan Jacobs, MD, review efficacy data from the indirect comparison study of acalabrutinib versus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia.
Clinical Trials With BTK Inhibitors in Relapsed/Refractory CLL
Focused discussion on key clinical trial data behind currently available BTK inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia.
Relapsed/Refractory CLL: Overview of the Treatment Landscape
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
